nerd

08 Aug 2026

08 Aug 2026 1:12am GMT

Should AI labs be treated like the owners of dangerous animals?

08 Aug 2026 12:03am GMT

07 Aug 2026

Slashdot

Virginia Governor To Intervene In Dominion-NextEra Merger

Longtime Slashdot reader schwit1 shares an opinion piece from the Washington Post, written by Virginia Governor Abigail Spanberger: NextEra Energy, a Florida-based utility company, has filed paperwork to buy Dominion Energy for about $67 billion, creating the largest regulated electric utility in the world. Virginia's State Corporation Commission is the regulatory body tasked with reviewing the application, and the SCC's commissioners will ultimately decide whether to approve, deny or impose new conditions on any potential merger. As a Virginian, I am deeply skeptical about whether selling our primary state-regulated utility to an out-of-state company is good for the commonwealth. I have serious questions about what this deal would mean for us. And as governor, I intend to get answers and be a voice for Virginians in the process. That is why I will be taking the legal step of "intervening" in this proposed merger, which means that as governor, I will formally request to be a party to the case. I know this action is unprecedented by a Virginia governor -- but so, too, is the size of this proposed merger and its potential impact on the commonwealth. Virginians deserve to know that their leaders are laser-focused on ensuring that their needs are part of the SCC review. "If two large corporations stand to benefit financially from this merger, so, too, should the Virginians who pay the bills," said Spanberger. "That is why any potential deal must deliver a more affordable energy bill with sustained, long-term energy cost savings." By formally intervening in the merger review, Spanberger's administration would gain legal standing to participate directly in the case, request detailed information, raise concerns, and advocate for conditions that benefit people in the state. She says the goal is to push for lower long-term energy costs, protect utility jobs, and ensure any new owner continues investing in reliable, affordable and cleaner power.

Hacker News

U.S. Department of Energy Launches the Genesis Open Models Initiative

Comments

07 Aug 2026 10:24pm GMT

Slashdot

Water Utilities Group Partners With DEF CON Offshoot For Water Watch Center

The National Rural Water Association has partnered with DEF CON Franklin to launch the Water Watch Center, which will provide threat intelligence and cybersecurity services to smaller U.S. water utilities serving fewer than 10,000 people. The initiative comes amid a growing wave of cyberattacks on water systems across multiple states. The Record reports: The program will see five managed detection and response providers work with DEF CON Franklin and the NRWA to offer cyber services for water utilities serving fewer than 10,000 people. There are over 50,000 community water systems across the U.S. and 91% of them serve fewer than 10,000 people. "These leading cyber firms and NRWA are architecting a scalable cyber delivery model that has eluded water industry and national security officials to date," said Jake Braun, the co-founder of DEF CON Franklin and former cyber official in the Biden administration. "Our incredible Franklin volunteers will support the effort to keep costs down for cash-strapped utilities fending off adversaries like the Iranian Red Guard or Chinese Military," Braun said. "To further accelerate the effort, we hand-picked cyber providers who already support water utilities. These folks walk in the door knowing the intricacies of cybersecurity in a water utility environment." The providers include Rapid7, Defendify, Legato Security, L1 Secure and Sentinel Technologies. The companies will share threat information and data on vulnerability patches with the NRWA, which will operate as a hub.

Ars Technica

Europe's free satellite service just made it easier to track wildfires

Copernicus Browser adds wildfire visualization amid record wildfire season.

07 Aug 2026 9:48pm GMT

Flesh-eating screwworms feast on humans in Mexico; human cases top 500

Six deaths reported among screwworm cases, one directly attributed to the flies.

07 Aug 2026 9:09pm GMT

Slashdot

Kalshi and Polymarket Bets On Clinical Trials Criticized As 'Ghastly'

An anonymous reader quotes a report from NPR: Billions of dollars are traded every week on the lightly regulated prediction market sites, where users bet on everything from movie reviews to elections to conflicts in the Middle East. Clinical trials are just the latest area where the industry's rapid growth is raising ethical questions. Kalshi claims such bets will provide a new source of information about which drugs will get approved, and what clinical trials will show promising results, which the company says can help investors decide what new drugs to fund. "If you want to ban profiting from the failure of clinical trials, you would start with the stock market, where the financial incentive for this type of profit is orders of magnitude larger," said Kalshi spokesman Jack Such, pointing to stock market short sellers who have profited from clinical trial failures. "While Kalshi and the stock market are the same in this regard, they do differ in one important way: the stock market doesn't give any valuable information to researchers," Such said. Drug trial researchers, though, are far from convinced. David Tsai, who runs clinical trials at a biotech company in the San Francisco Bay Area, started an online petition pushing for such betting to be banned, making the case that betting on drug trials "threatens the very foundation of trust and integrity in biotechnology." Tsai is concerned that the prospect of betting provides those involved with a clinical trial a reason to tamper with the results for a prediction market payout. "If we were running a trial for an oncology drug that requires an infusion, a pharmacist who had placed a bet saying that it's gonna work well, or doesn't work well, could obviously adjust the infusion rate, could adjust the source temperature of the drug," he said. "They could change any number of variables that could obviously have a direct impact [on] how the trial and the data and the patient safety would come out." Another skeptic is Nicholas Zaorsky, a professor of radiation oncology at the Mayo Clinic in Jacksonville, Fla., who has helped run clinical trials and agrees that prediction markets can interfere with the advancement of life-saving drugs. "Prediction markets can be valuable in some settings because they aggregate information, but clinical trials are fundamentally different: investigators, coordinators, and sometimes even participants can directly influence aspects of the outcomes being wagered on," Zaorsky said. "That creates financial incentives that risk undermining trial integrity." Bettors should not be rooting for an experimental medicine to fail just to earn a buck, says Joshua Pederson, the father of a 12-year-old cancer patient enrolled in a clinical trial. "It's a dark idea," he said. "It's quite ghastly." Kalshi, for its part, argues that its prediction markets could help patients track promising medical breakthroughs and clinical trials, enlisting experts including 23andMe founder Anne Wojcicki to make the case. "Most patients don't know about the choices available in clinical trials or which programs are most promising. The opportunity to have an open, transparent dataset about trial probabilities is extremely promising and empowering for people," a white paper sponsored by Kalshi stated.